Physician profile
Eddie A Lim
NPI 1164439683
$19,219.81
in general payments reported to CMS, 2019-2025
24 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,784 · 2020: $1,900 · 2021: $2,624 · 2022: $3,833 · 2023: $2,761 · 2024: $3,255 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,071 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,070.99 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,001.37 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $2,330.27 | 2021-2025 | |
| Gilead Sciences, INC. | $2,217.88 | 2019-2025 | Vemlidy, Livdelzi |
| Janssen Pharmaceuticals, INC | $1,896.21 | 2019-2022 | |
| Novo Nordisk INC | $1,662.36 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $1,540.81 | 2019-2025 | |
| Amarin Pharma, INC. | $1,354.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $918.88 | 2019-2024 | Jardiance, Ofev, Tradjenta |
| Lilly USA, LLC | $816.94 | 2019-2023 | Jardiance, Emgality |
| Amgen INC. | $752.73 | 2020-2024 | Krystexxa |
| Glaxosmithkline, LLC. | $574.40 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.34 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $265.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $246.95 | 2019-2023 | |
| Dexcom, INC. | $235.98 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $231.43 | 2019 | |
| Corcept Therapeutics | $223.71 | 2022-2023 | Korlym |
| Biotronik Nro, INC. | $160.72 | 2024 | Prospera |
| Ironwood Pharmaceuticals, INC | $131.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $126.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.71 | 2022 | |
| Merck Sharp & Dohme LLC | $88.08 | 2019 | |
| Allergan, INC. | $33.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.